Athira Pharma Inc
ATHA
Get informed when a big investor buys or sells
+ FollowCurrent Fair Value
81.8% upsideUndervalued by 81.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $26.62 Million |
|---|---|
| Enterprise Value | $-5,520,763.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-24.7 |
| Beta | 2.8 |
| Outstanding Shares | 19,027,087 |
Return
| Return on Equity | -262.49% |
|---|---|
| Return on Assets | -180.77% |
| Return on Invested Capital | -170.35% |
Valuation & Multiples
| P/E Ratio | -1.42 |
|---|---|
| PEG | -0.55 |
| Price to Sales | - |
| Price to Book Ratio | 3.38 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.05 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.13 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 157.34%▲ 114.00% |
|---|---|
| Total Invested | $46.70M▲ 514.95% |
| Investors Holding | 42▲ 9.00% |
ESG Score
No data
About Athira Pharma Inc
Relevant Senate Committees
This powerful committee controls taxation, trade, and entitlement spending like Medicare. Its decisions on corporate tax policy and 'Medicare pricing' directly impact the profitability and market for Athira Pharma's biological products.
This committee directly allocates federal spending, including 'scientific research.' Its subcommittees determine the precise funding for agencies like NIH, which are critical for biotech R&D and could directly impact Athira Pharma's order books if it receives federal grants or contracts.
This committee directly regulates the FDA and NIH, which are primary regulatory and funding bodies for biological product manufacturers. Its oversight of drug approval processes and research directly impacts Athira Pharma's core business.
Intellectual property (patents) and antitrust laws are critical for biotech companies. This committee's oversight of the DOJ, antitrust, and IP directly influences mergers, market competition, and patent protection essential to Athira Pharma's business.